Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity

Eur J Cancer. 1997 Aug;33(9):1345-6. doi: 10.1016/s0959-8049(97)00184-6.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Cost-Benefit Analysis
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / economics
  • Interferon-alpha / therapeutic use*
  • Melanoma / economics
  • Melanoma / therapy*
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins